To Boost Or Not To Boost? Pfizer, FDA, And The COVID Vaccine Communication Challenge

Pfizer’s bid for third dose appears to get pushback from the US government, but reticence about the booster may reflect PR considerations more than any fundamental concern about the vaccine.

Pfizer Inc.’s announcement that that it would be seeking authorization for a booster shot to its COVID vaccine raises a host of challenges for the US government, from what criteria it will use to evaluate the application, to how it will communicate with the public about the issue.

Health officials have long acknowledged the near inevitability of boosters. (Also see "US Gov't Plans To Control COVID Vaccine...

More from Vaccines

More from Pink Sheet